Global research trends in single-port robot-assisted radical prostatectomy: a visualization-based bibliometric...

This study employs bibliometric methods to systematically analyze research hotspots and evolving trends in the field of single-port robot-assisted radical prostatectomy (SP-RARP). By searching the Web of Science Core Collection (WoSCC) for relevant literature from 2008 to 2025, a total of 271 records were ultimately included. Co-occurrence networks for countries, institutions, scholars, journals, and keywords were then visualized and subjected to cluster analysis. The results indicate that the number of publications in this field has experienced a notable increase since 2019, with 187 papers produced between 2020 and 2025, and the total citation count peaking in 2025 (reaching 1,107 citations). In terms of national contributions and collaboration networks, the United States accounts for the highest publication volume (164 articles) and, alongside Italy, forms the central nodes of the global collaboration network. China ranks third in publication volume, while countries such as the UK, South Korea, and France demonstrate notable activity in transnational collaboration. The Cleveland Clinic Foundation records the highest institutional output, with scholars such as Simone Crivellaro identified among the most active contributors in this field; relevant findings are predominantly published in specialized journals such as the Journal of Endourology. Keyword evolution indicates that the research focus has shifted from early explorations of minimally invasive approaches and surgical feasibility to in-depth studies on complication control, optimization of functional outcomes, and advanced perioperative care practices using dedicated single-port platforms. In summary, SP-RARP has expanded the strategies for minimally invasive treatment of prostate cancer and demonstrates potential for optimizing perioperative outcomes. However, given the evolution of new technologies, there remains a clear need to design rigorous, high-quality clinical trials to further solidify the evidence base for its long-term oncological and functional benefits.